小细胞肺癌中EphA7表达及其临床意义  

Expression of EphA7 in small cell lung cancer and its clinical significance

作　　者：王佩 王婧雅 范雪涵 张宇嘉 黄鼎智 WANG Pei;WANG Jingya;FAN Xuehan;ZHANG Yujia;HUANG Dingzhi(Department of Thoracic Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy,Tianjin’s Clinical Research Center for Cancer,Tianjin Diagnosis and Treatment Center of Lung Cancer,Tianjin 300060,China)

机构地区：[1]天津医科大学肿瘤医院肺部肿瘤内科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心天津市肺癌诊治中心

出　　处：《肿瘤》2019年第7期558-567,共10页Tumor

摘　　要：目的:探讨酪氨酸蛋白激酶受体A7(Ephrin receptor A7,EphA7)在小细胞肺癌(small cell lung cancer,SCLC)患者中的表达情况及其临床意义。方法:分别利用CCLE(Cancer Cell Line Encyclopedia)和Oncomine数据库分析EphA7 mRNA在SCLC细胞系和组织中的表达水平。收集2011年1月—2014年12月于天津医科大学肿瘤医院接受肺叶切除术或全肺切除术的SCLC患者的石蜡包埋肺癌组织标本73例和癌旁肺组织标本6例,采用免疫组织化学法检测EphA7蛋白表达情况。采用χ^2检验分析EphA7蛋白表达与其他临床病理特征的关系,并用Kaplan-Meier生存曲线及COX风险比例模型分析EphA7蛋白表达水平及其他临床病理学特征与SCLC患者预后的关系。结果:在CCLE数据库包含的1 457个细胞系中,SCLC细胞系的EphA7 mRNA表达水平最高。在Oncomine数据库检索到的3个SCLC组织EphA7 mRNA表达数据集中,无论与正常肺组织还是非小细胞肺癌相比,SCLC组织的EphA7 mRNA表达水平均相对升高。73例SCLC患者的EphA7蛋白表达阳性率为72.6%(53/73),EphA7蛋白表达与淋巴结转移及TNM分期有关(P值均<0.05)。调整其他因素的影响后,EphA7蛋白表达阳性是影响SCLC患者总生存期(overall survival,OS)的独立预后因素[风险比(hazard ratio,HR)=2.369,95%置信区间(condence interval,CI)为1.075~5.219,P<0.05],而TNM分期是影响SCLC患者OS和无进展生存期(progression-free survival,PFS)的独立预后因素(HR=2.273,95%CI为1.252~4.124,P<0.05;HR=1.898,95%CI为1.088~3.312,P<0.05)。结论:SCLC细胞和组织中EphA7 mRNA与蛋白高表达。EphA7蛋白表达及肿瘤TNM分期可能与SCLC患者的预后密切相关。Objective:To explore the expression of Ephrin receptor A7(EphA7)in the patients with small cell lung cancer(SCLC)and its clinical significance.Methods:The expression of EphA7 mRNA in SCLC cell lines and tissues was analyzed by the Cancer Cell Line Encyclopedia(CCLE)and Oncomine databases,respectively.Seventy-three paraffin-embedded lung cancer specimens and six adjacent normal lung tissue samples from SCLC patients who underwent lobectomy or pneumonectomy resection in Tianjin Medical University Affiliated Cancer Hospital and Institution from January 2011 to December 2014 were collected.The expression of EphA7 protein was assessed by immunohistochemistry.The relationship between the expression of EphA7 protein and other clinicopathological factors was analyzed byχ^2 test.Kaplan-Meier survival curve and COX proportional hazard model were used to analyze the relationship between these clinicopathological parameters(including EphA7 expression)and the prognosis of SCLC patients.Results:The expression of EphA7 mRNA in SCLC cell lines was the highest among the 1 457 cell lines included in CCLE database.Three datasets of EphA7 mRNA expression in SCLC tissues were obtained from the Oncomine database.Compared with the normal lung tissues and non-small cell lung cancer,the expression level of EphA7 mRNA was relatively higher in SCLC tissues.The positive expression rate of EphA7 protein reached 72.6%(53/73)in the 73 patients with SCLC.The expression of EphA7 protein was significantly associated with lymph node metastasis and TNM stage(both P<0.05).After adjusting other factors,it was found that the positive expression of EphA7 protein was an independent prognostic factor for the overall survival(OS)of SCLC patients[hazard ratio(HR)=2.369,95%confidence interval(CI):1.075-5.219,P<0.05],while TNM stage was an independent prognostic factor for both OS(HR=2.273,95%CI:1.252-4.124,P<0.05)and progression-free survival(PFS)(HR=1.898,95%CI:1.088-3.312,P<0.05)of SCLC patients,respectively.Conclusion:EphA7 mRNA and protein are highly e

关 键 词：小细胞肺癌 预后 受体 EphA7 免疫组织化学 CCLE Oncomine数据库 

分 类 号：R734.2[医药卫生—肿瘤]